1.74

11.22% -0.22

After Hours: 1.76 0.02 +1.15%

Ocugen Inc (OCGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ocugen Inc stock is traded at $1.74, with a volume of 8.21M. It is down -11.22% in the last 24 hours and up +30.83% over the past month. Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Previous Close:

$1.96

Open:

$1.94

24h Volume:

8.21M

Relative Volume:

1.61

Market Cap:

$569.54M

Revenue:

Net Income/Loss:

$-63.08M

P/E Ratio:

-6.4444

EPS:

-0.27

Net Cash Flow:

$-72.53M

1W Performance:

-6.95%

1M Performance:

+30.83%

6M Performance:

+68.93%

1Y Performance:

+203.40%

1-Day Range:

$1.70

$1.96

1-Week Range:

$1.66

$2.00

52-Week Range:

$0.515

$2.00

Ocugen Inc Stock (OCGN) Company Profile

Name

Ocugen Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

484-328-4701

Address

11 GREAT VALLEY PARKWAY, MALVERN, PA

Employee

Twitter

@Ocugen

Next Earnings Date

2025-08-01

Latest SEC Filings

OCGN's Discussions on Twitter

Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCGN Ocugen Inc	1.74	641.55M	0	-63.08M	-72.53M	-0.27
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-15-24	Initiated	Maxim Group	Buy
Mar-01-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Aug-23-22	Initiated	Mizuho	Buy
Jun-15-22	Resumed	ROTH Capital	Buy
Jun-02-22	Initiated	Cantor Fitzgerald	Overweight
Jul-26-21	Initiated	Noble Capital Markets	Outperform
Jun-11-21	Downgrade	ROTH Capital	Buy → Neutral
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-04-21	Upgrade	H.C. Wainwright	Neutral → Buy

View All

Ocugen Inc Stock (OCGN) Latest News

01:42 AM

Ocugen, Inc. Hits New 52-Week High of $2.00, Marking Major Milestone - Markets Mojo

09:09 AM

08:14 AM

Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript - Insider Monkey

08:14 AM

Ocugen Inc (OCGN)

Ocugen Inc Stock (OCGN) Company Profile

Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Ocugen Inc Stock (OCGN) Latest News

Ocugen (NASDAQ:OCGN) Trading Down 7.2%Here's Why - MarketBeat

OCGN Analyst Rating Maintained by Chardan Capital at Buy with $7 - GuruFocus

Ocugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan Capital - MarketBeat

Ocugen, Inc. Hits New 52-Week High of $2.00, Marking Major Milestone - Markets Mojo

Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript - Insider Monkey

Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq

Ocugen Q4 2025 Earnings Call Transcript - MarketBeat

Ocugen 2025 Financial Results: Quarterly and Annual ReportNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform

Ocugen (OCGN) Q4 2025 Earnings Call Transcript - The Globe and Mail

Ocugen files petition in Delaware court to validate share increase amendment - Investing.com Nigeria

Ocugen (OCGN) Advances Gene Therapy Trials and Strengthens Leade - GuruFocus

Ocugen (NASDAQ:OCGN) Shares Gap DownWhat's Next? - MarketBeat

Ocugen (OCGN) Reports Q4 Earnings and Cash Position Update - GuruFocus

Ocugen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - Ocugen, Inc.

Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M - TradingView

Ocugen (NASDAQ: OCGN) advances RP, GA and Stargardt gene therapies - Stock Titan

Ocugen Seeks Court Validation of Charter Amendment Dispute - TipRanks

Ocugen (NASDAQ:OCGN) Announces Earnings Results - MarketBeat

Court petition over Ocugen (NASDAQ: OCGN) share increase vote - Stock Titan

Ocugen (NASDAQ: OCGN) advances eye gene therapies and extends cash runway - Stock Titan

Ocugen, Inc. completes OCU400 Phase 3 and secures first OCU400 licensing deal amid leadership boost - Traders Union

Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com Nigeria

Ocugen Q4 Earnings Call Highlights - Yahoo Finance

OCGN: Advanced gene therapy pipeline, strong clinical data, and extended cash runway into late 2026 - TradingView

Ocugen reports Q4 EPS (6c), consensus (6c) - TipRanks

OCGN: OCU400 Phase 3 enrollment completed; strong pipeline progress and extended cash runway - TradingView

Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Ocugen (OCGN) Achieves Significant Milestones in 2025 - GuruFocus

OCUGEN ($OCGN) Releases Q4 2025 Earnings - Quiver Quantitative

OCGN: Advanced gene therapy pipeline and secured financing, extending cash runway into late 2026 - TradingView

Ocugen Completes Enrollment in OCU400 Phase 3 Clinical Trial for Retinitis Pigmentosa, Prepares for Major 2027 Data Announcements - Quiver Quantitative

Earnings Summary: Ocugen Q4 - Benzinga

BRIEF-Ocugen Q4 EPS USD -0.06 - TradingView

Gene therapy push for blindness: how Ocugen plans to fund it - Stock Titan

OCGN Earnings History & Surprises | EPS & Revenue Results | OCUGEN INC (NASDAQ:OCGN) - ChartMill

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Ocugen: Fourth Quarter Financial Results Overview - Bitget

Examining the Future: Ocugen's Earnings Outlook - Benzinga

OCGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Ocugen (NASDAQ:OCGN) Sets New 1-Year HighStill a Buy? - MarketBeat

Ocugen Inc. stock rises Monday, outperforms market - MarketWatch

Key facts: Ocugen completes patient enrollment for OCU400 trial; 6-cent loss per share expected - TradingView

Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete - TipRanks

Ocugen completes enrollment in phase 3 retinitis pigmentosa trial - Investing.com

Ocugen Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView

Ocugen (OCGN) Completes Enrollment for Phase 3 OCU400 Trial - GuruFocus

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - Bitget

Ocugen, Inc. advances gene therapies for rare inherited retinal diseases amid global support - Traders Union

Ocugen Inc. stock falls Friday, underperforms market - MarketWatch

Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com

Ocugen Inc Stock (OCGN) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to OCGN